• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LEF1 高表达与实体瘤预后不良相关，但与血液肿瘤无关：一项荟萃分析。

High expression of LEF1 correlates with poor prognosis in solid tumors, but not blood tumors: a meta-analysis.

机构信息

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China.

Hubei Institute of Urology, Wuhan 430030, P.R. China.

出版信息

Biosci Rep. 2020 Sep 30;40(9). doi: 10.1042/BSR20202520.

DOI:10.1042/BSR20202520
PMID:32856045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7468095/
Abstract

BACKGROUND

Previously published studies have indicated that lymphoid enhancer-binding factor 1 (LEF1) expression could be recognized as a valuable biomarker to evaluate clinical outcome for various types of malignant cancer, but the results remained controversial. Therefore, we conducted this meta-analysis to pool the published estimates and discuss the relationship of LEF1 expression with cancer prognosis.

METHODS

Five electronic databases Pubmed, Web of Science, Embase, CNKI, and Wanfang were systematically searched for eligible literatures. Hazard ratios (HRs) and 95% confidence intervals (CIs) from the included studies were combined to estimate the effect of LEF1 expression on cancer patients' survival.

RESULTS

Eleven original studies met the criteria and were enrolled for analysis. The results indicated that compared with patients in low LEF1 expression group, patients in high LEF1 expression group tended to have shorter overall survival (HR = 1.74, 95% CI: 1.06-2.86, P=0.029), especially for patients with solid tumors (HR = 2.39, 95% CI: 1.86-3.08, P=0.000).

CONCLUSIONS

Individual evidence about the prognostic value of LEF1 expression in human cancers was limited. Our meta-analysis supported the suggestion that elevated LEF1 expression could function as a promising biomarker to predict the clinical outcomes for malignant cancers, especially solid tumors. More high-quality clinical studies are warranted to highlight the prognostic value of LEF1 expression in human cancers.

摘要

背景

先前的研究表明，淋巴增强因子结合因子 1（LEF1）的表达可以被认为是评估各种恶性肿瘤临床结局的有价值的生物标志物，但结果仍存在争议。因此，我们进行了这项荟萃分析，以汇总已发表的评估结果，并讨论 LEF1 表达与癌症预后的关系。

方法

系统检索了 Pubmed、Web of Science、Embase、CNKI 和万方五个电子数据库中的相关文献。纳入研究的风险比（HRs）和 95%置信区间（CIs）被合并，以评估 LEF1 表达对癌症患者生存的影响。

结果

符合标准的 11 项原始研究被纳入分析。结果表明，与 LEF1 低表达组患者相比，LEF1 高表达组患者的总生存期更短（HR=1.74，95%CI：1.06-2.86，P=0.029），尤其是实体瘤患者（HR=2.39，95%CI：1.86-3.08，P=0.000）。

结论

关于 LEF1 表达在人类癌症中的预后价值的个体证据有限。我们的荟萃分析支持了这样一种观点，即升高的 LEF1 表达可以作为预测恶性肿瘤临床结局的有前途的生物标志物，尤其是实体瘤。需要更多高质量的临床研究来强调 LEF1 表达在人类癌症中的预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/48a9964b8c23/bsr-40-bsr20202520-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/cc12d5f11237/bsr-40-bsr20202520-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/cb1c36fb497f/bsr-40-bsr20202520-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/d066c780aa4f/bsr-40-bsr20202520-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/ced4300bf5fa/bsr-40-bsr20202520-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/2e84265e7396/bsr-40-bsr20202520-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/5193335747df/bsr-40-bsr20202520-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/48a9964b8c23/bsr-40-bsr20202520-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/cc12d5f11237/bsr-40-bsr20202520-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/cb1c36fb497f/bsr-40-bsr20202520-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/d066c780aa4f/bsr-40-bsr20202520-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/ced4300bf5fa/bsr-40-bsr20202520-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/2e84265e7396/bsr-40-bsr20202520-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/5193335747df/bsr-40-bsr20202520-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fdf/7468095/48a9964b8c23/bsr-40-bsr20202520-g7.jpg

相似文献

1
High expression of LEF1 correlates with poor prognosis in solid tumors, but not blood tumors: a meta-analysis.LEF1 高表达与实体瘤预后不良相关，但与血液肿瘤无关：一项荟萃分析。
Biosci Rep. 2020 Sep 30;40(9). doi: 10.1042/BSR20202520.
2
Association between Alpha B-crystallin expression and prognosis in patients with solid tumors: A protocol for systematic review and meta-analysis.αB-晶状体蛋白表达与实体瘤患者预后的相关性：系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Feb 19;100(7):e24831. doi: 10.1097/MD.0000000000024831.
3
Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis.长链非编码 RNA SNHG16 在人类癌症中的表达的临床病理意义和预后：一项荟萃分析。
BMC Cancer. 2020 Jul 16;20(1):662. doi: 10.1186/s12885-020-07149-w.
4
Increased Sphingosine Kinase 1 Expression Is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis.丝氨酸棕榈酰转移酶 1 表达增加与人类实体瘤预后不良相关：一项荟萃分析。
Dis Markers. 2022 Jan 28;2022:8443932. doi: 10.1155/2022/8443932. eCollection 2022.
5
Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors.长链非编码 RNA FOXD2-AS1 表达对实体瘤患者的预后价值。
Pathol Res Pract. 2019 Sep;215(9):152449. doi: 10.1016/j.prp.2019.152449. Epub 2019 Jun 8.
6
Prognostic value of lncRNA FEZF1 antisense RNA 1 over-expression in oncologic outcomes of patients with solid tumors.长链非编码RNA FEZF1反义RNA 1过表达在实体瘤患者肿瘤学预后中的预测价值
Medicine (Baltimore). 2019 Jun;98(24):e15982. doi: 10.1097/MD.0000000000015982.
7
Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients.LEF1 表达增加和 Notch2 表达减少是结直肠癌患者预后不良的强烈预测指标。
Dis Markers. 2013;35(5):395-405. doi: 10.1155/2013/983981. Epub 2013 Sep 26.
8
Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis.SNHG6 在癌症中的临床病理和预后价值：系统评价和荟萃分析。
BMC Cancer. 2020 Apr 22;20(1):343. doi: 10.1186/s12885-020-06850-0.
9
Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.三结构域蛋白 44 的表达及其在人类恶性肿瘤中的预后和临床病理价值：一项荟萃分析。
BMC Cancer. 2020 Jun 5;20(1):525. doi: 10.1186/s12885-020-07014-w.
10
Prognostic value of association of OCT4 with LEF1 expression in esophageal squamous cell carcinoma and their impact on epithelial-mesenchymal transition, invasion, and migration.OCT4 与 LEF1 表达的相关性对食管鳞癌的预后价值及其对上皮-间质转化、侵袭和迁移的影响。
Cancer Med. 2018 Aug;7(8):3977-3987. doi: 10.1002/cam4.1641. Epub 2018 Jul 4.

引用本文的文献

1
Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer.硫酸软骨素蛋白聚糖 4 为预防卵巢癌腹膜扩散提供新的治疗方法。
Int J Mol Sci. 2024 Jan 28;25(3):1626. doi: 10.3390/ijms25031626.

本文引用的文献

1
The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma.转录因子 LEF1 促进食管鳞状细胞癌的肿瘤发生并激活 TGF-β 信号通路。
J Exp Clin Cancer Res. 2019 Jul 11;38(1):304. doi: 10.1186/s13046-019-1296-7.
2
Expression of LEF1 and TCF1 (TCF7) proteins associates with clinical progression of nasopharyngeal carcinoma.LEF1 和 TCF1（TCF7）蛋白的表达与鼻咽癌的临床进展相关。
J Clin Pathol. 2019 Jun;72(6):425-430. doi: 10.1136/jclinpath-2019-205698. Epub 2019 Mar 27.
3
Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway.
淋巴增强结合因子 1 通过直接激活 NOTCH 通路促进肝癌干细胞特性和低分化。
Oncogene. 2019 May;38(21):4061-4074. doi: 10.1038/s41388-019-0704-y. Epub 2019 Jan 29.
4
The global cancer burden: necessity is the mother of prevention.全球癌症负担：必要性是预防之母。
Nat Rev Cancer. 2019 Mar;19(3):123-124. doi: 10.1038/s41568-019-0110-3.
5
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家按年龄、性别和死因分类的死亡率，195 个国家和地区，1980-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
6
Prognostic value of association of OCT4 with LEF1 expression in esophageal squamous cell carcinoma and their impact on epithelial-mesenchymal transition, invasion, and migration.OCT4 与 LEF1 表达的相关性对食管鳞癌的预后价值及其对上皮-间质转化、侵袭和迁移的影响。
Cancer Med. 2018 Aug;7(8):3977-3987. doi: 10.1002/cam4.1641. Epub 2018 Jul 4.
7
Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.癌症中的Wnt信号通路蛋白LEF1，作为一种预后生物标志物和治疗靶点。
Am J Cancer Res. 2017 Jun 1;7(6):1389-1406. eCollection 2017.
8
Cancer treatment and survivorship statistics, 2016.癌症治疗和生存统计，2016 年。
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
9
Hematopoietic and Leukemic Stem Cells Have Distinct Dependence on Tcf1 and Lef1 Transcription Factors.造血干细胞和白血病干细胞对Tcf1和Lef1转录因子有不同的依赖性。
J Biol Chem. 2016 May 20;291(21):11148-60. doi: 10.1074/jbc.M116.717801. Epub 2016 Apr 4.
10
Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia.淋巴样增强子结合因子-1（LEF1）的过表达是儿童急性淋巴细胞白血病中一种新的有利预后因素。
Int J Lab Hematol. 2015 Oct;37(5):631-40. doi: 10.1111/ijlh.12375. Epub 2015 May 8.